1,106 material Form 8-K filings that 909 companies we cover made with the SEC in June 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Mondelēz International said Amit Banati will become Executive Vice President and Chief Financial Officer on July 1, 2026, reporting to Chair and CEO Dirk Van de Put. Banati most recently served as CFO of Kenvue, Inc. from May 2025 to May 2026, and earlier as CFO of Kellanova and Kellogg. Luca Zaramella, who the company said served as CFO for eight years, will continue as Executive Vice President and Chief Operating Officer.
Start date: July 1, 2026; Banati will be a member of the Mondelēz International Leadership Team
Base salary of $1,050,000 with a 125% target annual incentive and a $5,000,000 target annual long-term equity grant for 2026
Make-whole cash award of up to $7,000,000 for compensation Banati must forfeit at his former employer, subject to repayment on certain termination events before the second anniversary of the start date
Luca Zaramella remains Executive Vice President and Chief Operating Officer
Tyson Foods entered into a Third Amended and Restated Employment Agreement with Chairman John H. Tyson on June 17, 2026, replacing his 2017 agreement. The filing sets a base salary of $3,500,000, a one-time incentive cash payment of $40,000,000, and a term ending September 30, 2029, with severance and security perks, which shareholders may view as a significant compensation commitment.
Initial term ends September 30, 2029, with automatic three-year renewals unless terminated.
Annual base salary of $3,500,000; annual incentive target of 300% of base salary; long-term incentive target grant value of $6,000,000.
One-time incentive award cash payment of $40,000,000, partly subject to pro-rata repayment if he resigns without Good Reason or is terminated for Cause before September 30, 2029.
Termination without Cause or for Good Reason triggers a lump sum payment, the greater of two years of target pay or the remaining term's pay, plus security services and life insurance premium reimbursement.
On June 18, 2026, the CEO, CFO and COO of M3-Brigade Acquisition V Corp. resigned, along with three directors, and the board named Chinh Chu, the company's President, as principal executive officer and Thomas Boychuk as CFO. The filing states that none of the resignations resulted from a disagreement with the company, and that neither appointee will receive compensation for the new role. The filing names M3-Brigade Acquisition V Corp., not Velos Acquisition I Corp. as the ticker VLOS suggests, so the registrant's identity should be confirmed.
Robert Rivas Collins resigned as CEO and Eric Greenhaus resigned as CFO, principal financial officer and principal accounting officer, both effective June 18, 2026
Matthew Perkal resigned as Chief Operating Officer and from the board, along with directors Mohsin Y. Meghji and Benjamin Fader-Rattner
Chinh Chu, President since May 2025 and a CC Capital founder, was appointed principal executive officer; Thomas Boychuk, 44, was appointed CFO
Neither Chu nor Boychuk will receive compensation for the new roles, and both are affiliated with the sponsor's parent CC Capital
CoreWeave completed a private offering of $1,250 million of 9.625% senior notes and €2,000 million of 8.500% senior notes, both maturing July 15, 2032. The company says it will use the proceeds for general corporate purposes, including repaying existing indebtedness, and to pay offering costs. The notes add to CoreWeave's debt obligations, and their terms include restrictive covenants limiting additional debt, dividends and asset sales.
USD Notes: $1,250 million at 9.625%, maturing July 15, 2032
EUR Notes: €2,000 million at 8.500%, maturing July 15, 2032
Interest paid semi-annually in cash, beginning January 15, 2027; interest accrues from June 18, 2026
Notes are senior unsecured, guaranteed by certain CoreWeave subsidiaries; optional redemption before July 15, 2029 includes a make-whole premium
Brady Corporation entered a $1.0 billion credit agreement on June 12, 2026, consisting of a $500 million term loan and a $500 million revolving credit facility, which replaced its prior 2019 credit agreement. The company says it will use the borrowings mainly to finance its pending acquisition of Honeywell's Productivity Solutions and Services business, which means the company will take on new debt tied to that deal.
Credit agreement dated June 12, 2026: $500 million term loan plus $500 million revolving credit facility, maturing June 12, 2031
Replaces previous credit agreement dated August 1, 2019; €13.0 million of revolving loans were exchanged and other obligations repaid in full
Revolver availability capped at $300 million until the PSS acquisition closes, then expands to the full $500 million
Maximum consolidated net leverage ratio of 3.50 to 1.00 (temporarily up to 4.00 to 1.00 after closing) and minimum interest coverage of 3.00 to 1.00
Pfizer said on June 18, 2026 that it is reaffirming all components of its full-year 2026 guidance, following its announcement of a Chief Financial Officer transition the same day. The guidance includes revenues of $59.5 billion to $62.5 billion and adjusted diluted EPS of $2.80 to $3.00, unchanged from the December 16, 2025 guidance and the May 5, 2026 reaffirmation.
Full-year 2026 revenue guidance reaffirmed at $59.5 billion to $62.5 billion
Adjusted diluted EPS guidance reaffirmed at $2.80 to $3.00
Guidance first issued December 16, 2025 and reaffirmed May 5, 2026 on the first quarter earnings call
Filing follows a Chief Financial Officer transition announcement made June 18, 2026
Chicago Atlantic Real Estate Finance (REFI) signed a merger agreement on June 17, 2026, under which it will elect to be regulated as a business development company and merge into Chicago Atlantic BDC (LIEN), with LIEN as the surviving public company. REFI stockholders would receive LIEN shares based on the ratio of each company's adjusted net asset value per share, and would be expected to own about 50.5% of the combined company based on March 31, 2026 figures, subject to the final ratio at closing.
Exchange is based on adjusted NAV per share at closing; REFI holders would be expected to own about 50.5% of LIEN based on March 31, 2026 NAVs.
REFI's current management agreement with its manager terminates automatically at the BDC election, without termination payment.
Closing is expected in the fourth quarter of 2026, subject to stockholder approvals at both companies and regulatory approvals.
Chicago Atlantic agreed to fund $2.0 million of REFI's transaction-related expenses at or immediately before closing.
Deluxe agreed on June 17, 2026 to acquire Celero Commerce, a payment processor for small to mid-sized businesses, for approximately $625 million in cash plus seller expenses and adjustments. The deal is funded with an incremental $375 million Term Loan A and drawings on Deluxe's existing revolving credit facility, and Deluxe expects net leverage of about 3.9x at closing. Deluxe reaffirmed its 2026 full-year guidance, which excludes Celero, and plans to update guidance after closing.
Purchase price of approximately $625 million in cash, funded by a $375 million incremental Term Loan A and the existing revolver
Deluxe expects net leverage of about 3.9x at closing and a return to below 3.0x within 24 months after closing
Celero reported over $200 million in 2025 revenue and a 28% adjusted EBITDA margin, per the company; Deluxe expects over $15 million in cost synergies by 2028
Closing is subject to regulatory approvals and customary conditions, with completion expected in the third quarter of 2026
Pfizer said Chief Financial Officer Dave Denton will leave the company on August 15, 2026 to take a consumer goods role outside the pharmaceutical industry. The company said the departure is not related to its financial or operating results. Cecile Guegan, a Pfizer finance executive since 2005, will serve as interim CFO from August 16 while Pfizer searches for a permanent successor.
Dave Denton notified Pfizer on June 16, 2026 that he will step down as CFO effective August 15, 2026
Cecile Guegan, Senior Vice President, Finance, Global Biopharmaceutical Business, becomes Interim CFO effective August 16, 2026
Pfizer is conducting a comprehensive internal and external search for a permanent successor
Chairman and CEO Albert Bourla credited Denton with leading transactions including Seagen, Biohaven and Metsera
Chicago Atlantic BDC (LIEN) signed a merger agreement under which REFI will elect to be regulated as a business development company and merge into LIEN in an all-stock deal, with LIEN continuing as the surviving public company. REFI stockholders would be expected to own about 50.5% of LIEN after closing, based on March 31, 2026 net asset values, and the final split depends on the NAV ratio calculated shortly before closing. Completion requires stockholder approvals at both companies, regulatory approvals and lender consents, with closing expected in the fourth quarter of 2026.
Former REFI stockholders would be expected to own approximately 50.5% of LIEN after the merger, based on March 31, 2026 NAVs; the final percentage depends on the closing NAV ratio.
Pro-forma NAV of $613 million and pro-forma portfolio of $771 million in investments, based on March 31, 2026 financial statements as reported on Form 10-Q.
LIEN board will consider in good faith a stock repurchase program of up to $25.0 million after closing, subject to market conditions.
Merger is currently expected to close in the fourth quarter of 2026; Chicago Atlantic has agreed to fund $2.0 million of REFI's transaction-related expenses.
Accenture reported third-quarter fiscal 2026 revenue of $18.72 billion, up 6% in U.S. dollars and 3% in local currency, and diluted EPS of $3.80, up 9%. It now expects full-year revenue growth of 3% to 4% in local currency, down from 3% to 5% in March, and raised the low end of its GAAP diluted EPS range to $13.38 to $13.50. Profit grew, but new bookings fell 2% and the revenue outlook was lowered.
Q3 FY26 revenue $18.72 billion, up 6% in U.S. dollars and 3% in local currency; diluted EPS $3.80 versus $3.49 a year earlier
Full-year FY26 local-currency revenue growth now 3% to 4%, versus 3% to 5% as of March 19, 2026
Full-year GAAP diluted EPS now $13.38 to $13.50, versus $13.25 to $13.50 previously
New bookings $19.32 billion, down 2% in U.S. dollars; free cash flow $3.6 billion; quarterly dividend of $1.63 per share payable August 14, 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.